floxuridine has been researched along with Nasopharyngeal Carcinoma in 2 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Nasopharyngeal Carcinoma: A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Concurrent carboplatin chemotherapy did not significantly improve the long-term survival after inductive carboplatin and floxuridine chemotherapy in locoregionally advanced nasopharyngeal carcinoma." | 5.20 | Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area. ( Cao, KJ; Guo, L; Guo, X; Hong, MH; Huang, PY; Mai, HQ; Mo, HY; Qian, CN; Wu, PH; Zeng, Q, 2015) |
| "To evaluate the benefits and risks of hepatic artery infusion (HAI) gemcitabine and floxuridine (FUDR) in patients with nasopharyngeal carcinoma liver metastases." | 3.96 | Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis. ( Li, G; Li, H; Peng, C; Shi, L; Zhou, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, C | 1 |
| Zhou, C | 1 |
| Li, G | 1 |
| Li, H | 1 |
| Shi, L | 1 |
| Huang, PY | 1 |
| Zeng, Q | 1 |
| Cao, KJ | 1 |
| Guo, X | 1 |
| Guo, L | 1 |
| Mo, HY | 1 |
| Wu, PH | 1 |
| Qian, CN | 1 |
| Mai, HQ | 1 |
| Hong, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter and Prospective Clinical Trial of Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT04522050] | Phase 1 | 65 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for floxuridine and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy, Ad | 2015 |
1 other study available for floxuridine and Nasopharyngeal Carcinoma
| Article | Year |
|---|---|
Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis.
Topics: Adult; Aged; Angiography, Digital Subtraction; Antineoplastic Combined Chemotherapy Protocols; Deoxy | 2020 |